However, although targeting ApoC3 by antisense oligonucleotide (ASO), volanesorsen, markedly reduces plasma TG level in patients with HTG (7, 8), the cholesterol-lowering effect of ApoC3 inhibition and then the consequential outcomes of atherosclerotic cardiovascular disease (ASCVD) have not been reported yet in patients with FH so far. The gene discussed is APOC3; the disease is atherosclerosis.